Literature DB >> 14533191

Rational development of a HIV-1 gene therapy vector.

D S Anson1,2, M Fuller1.   

Abstract

BACKGROUND: HIV-1 provides an attractive option as the basis for gene transfer vectors due to its ability to stably transduce non-cycling cell populations. In order to fully utilise the promise of HIV-1 as a vector it is important that the effects of viral cis sequence elements on vector function are carefully delineated.
METHODS: In this study we have systematically evaluated the effect of various cis elements from the HIV-1 YU-2 genome that have been implicated as either affecting vector performance, or HIV-1 replication, on the efficiency of vector production (titre and infectivity). As a measure of the relative safety of vectors their propensity to inadvertently transfer the gagpol gene to transduced cells was assessed.
RESULTS: Sequences that were found to increase vector titre were from the 5' end of the gag gene, from the 5' and 3' ends of the env gene, from immediately upstream of the polypurine tract, and the central polypurine tract. The substitution of the HIV-1 RRE with heterologous RNA transport elements, or the deletion of the RRE, resulted in greatly reduced vector titres. RNA analysis suggested that the role of the Rev/RRE system extends beyond simply acting as an RNA nuclear export signal. The relative safety of different vector designs was compared and an optimal construct selected.
CONCLUSIONS: Based on our results we have constructed a vector that is both more efficient, and has better safety characteristics, than the widely used pHR' HIV-1 vector construct. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 14533191     DOI: 10.1002/jgm.415

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  12 in total

1.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Reduced mobilization of Rev-responsive element-deficient lentiviral vectors.

Authors:  Susann Lucke; Thomas Grunwald; Klaus Uberla
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Cytoplasmic utilization of human immunodeficiency virus type 1 genomic RNA is not dependent on a nuclear interaction with gag.

Authors:  Bastian Grewe; Bianca Hoffmann; Inga Ohs; Maik Blissenbach; Sabine Brandt; Bettina Tippler; Thomas Grunwald; Klaus Uberla
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

4.  The HIV-1 Rev/RRE system is required for HIV-1 5' UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles.

Authors:  Adam S Cockrell; Henriette van Praag; Nicholas Santistevan; Hong Ma; Tal Kafri
Journal:  Retrovirology       Date:  2011-06-24       Impact factor: 4.602

5.  DDX1 is an RNA-dependent ATPase involved in HIV-1 Rev function and virus replication.

Authors:  Stephen P Edgcomb; Andrew B Carmel; Souad Naji; Geza Ambrus-Aikelin; Jason R Reyes; Andrew C S Saphire; Larry Gerace; James R Williamson
Journal:  J Mol Biol       Date:  2011-10-25       Impact factor: 5.469

6.  Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.

Authors:  Donald S Anson; Chantelle McIntyre; Belinda Thomas; Rachel Koldej; Enzo Ranieri; Ainslie Roberts; Peter R Clements; Kylie Dunning; Sharon Byers
Journal:  Genet Vaccines Ther       Date:  2007-01-16

7.  Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation.

Authors:  Sabine Brandt; Maik Blissenbach; Bastian Grewe; Rebecca Konietzny; Thomas Grunwald; Klaus Uberla
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

8.  Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repair.

Authors:  Rachel M Koldej; Donald S Anson
Journal:  BMC Biotechnol       Date:  2009-10-07       Impact factor: 2.563

9.  The HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA.

Authors:  Bastian Grewe; Katrin Ehrhardt; Bianca Hoffmann; Maik Blissenbach; Sabine Brandt; Klaus Uberla
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

10.  The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery.

Authors:  Donald S Anson
Journal:  Genet Vaccines Ther       Date:  2004-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.